The molecule is a tripeptide three amino acids (glycine, histidine, lysine) bound to a copper ion that the human body produces naturally in plasma
In the Phase 2 obesity trial published in NEJM in 2023, retatrutide at the 12 mg weekly dose produced a mean placebo-adjusted body weight reduction of 22.1 percentage points (22.1% (24.2% arm) mean absolute reduction on the retatrutide arm) at 48 weeks (Jastreboff et al., NEJM, 2023)
It is used clinically for various conditions, including chronic viral infections like hepatitis B, certain cancers, and sepsis, to improve immune response and reduce inflammation
This is specific to retatrutide and not typically seen with cagrilintide
BPC-157 takes effect at different rates, depending on tissue type, injury severity, and administration consistency